Targeted Cancer Therapy Has Been Defined at a Narrow Biological Level—A Hierarchical and Semi-Quantitative Reassessment of Genomic, Redox, and Metabolic Targeting

1. The Targeted Therapy Paradigm Reconsidered

The phrase “targeted therapy” carries three implicit promises:

• Precision
• Broad applicability
• Comprehensive tumor control

The data robustly support the first promise. They do not consistently support the latter two.

In this context, ‘targeted’ should be understood as referring to molecular specificity, not population-wide effectiveness.

1.1. Population-Level Impact

Marquart et al. (2018) estimated that approximately 15.4% of metastatic cancer patients were eligible for genome-driven therapy, with an estimated 4.9% deriving clinical benefit [1].

Haslam et al. (2021) reported updated estimates of approximately 13.6% eligibility and ~7.0% response in 2020[2].

Even under modern assumptions, mutation-matched targeted therapy remains a minority-impact modality at the population level.

1.2. Tumor-Cell Coverage: Intratumoral Heterogeneity

Multi-region sequencing studies demonstrate that many tumors are not genomically uniform.

Gerlinger et al. reported that 63–69% of somatic mutations were not ubiquitous across sampled tumor regions [3].

In TRACERx NSCLC, median mutation heterogeneity was approximately 30%, with ~48% heterogeneous copy-number alterations [4].

Thus, even within eligible patients, mutation-layer targeting may not encompass all malignant clones present within a tumor ecosystem.

1.3. Durability Constraints

Durability of response further narrows effective impact. Examples include:

• Osimertinib in EGFR-mutant NSCLC: median progression-free survival (PFS) ~18–19 months [5].
• Sotorasib in KRAS G12C NSCLC: median PFS ~6–7 months [6].
• Dabrafenib plus trametinib in BRAF-mutant melanoma: ~34% 5-year overall survival [7].

Acquired resistance is an expected evolutionary consequence of selective pressure at a single genomic node [8,9].

Interim Conclusion

Genomic targeted therapy is highly precise. However, it is simultaneously:

• Population-restricted
• Clone-restricted
• Evolutionarily constrained

Molecular specificity at a single genomic locus does not equate to comprehensive tumor-system control. A therapy may be exquisitely specific yet structurally narrow in biological reach. Conflating precision with breadth has shaped oncology doctrine more than the distributed architecture of cancer biology itself.

Cancer biology is organized around shared functional hallmarks rather than isolated mutational events [10,11]. Non-oncogene dependencies and stress-adaptation programs—including oxidative buffering, replication stress tolerance, and proteostasis maintenance—represent distributed liabilities that transcend individual driver mutations [12,13,14,15].

2. Layer 1—Genomic Targeted Therapy: Precision With Structural Breadth Limits

2.1. Population-Level Eligibility

Marquart et al. (2018) estimated [1]:

• 15.4% eligibility for genome-informed therapy
• 4.9% estimated response benefit

Haslam et al. (2021) updated these figures [2]:

• ~13.6% eligibility
• ~7.0% response estimate

Thus, population-level effective reach remains in low single-digit to low-teen ranges.

2.2. Tumor-Cell Coverage: Intratumoral Heterogeneity

Gerlinger et al.:

• 63–69% of somatic mutations not ubiquitous across tumor regions [3]

TRACERx NSCLC:

• ~30% median mutation heterogeneity [4]
• ~48% heterogeneous copy-number alterations [4]

Implication: mutation-layer targeting frequently does not cover all malignant clones within an individual tumor.

2.3. Durability Constraints

Examples:

• Osimertinib (EGFR NSCLC): median PFS ~18–19 months [5].
• Sotorasib (KRAS G12C): median PFS ~6–7 months [6].
• Dabrafenib + trametinib (BRAF melanoma): ~34% 5-year OS [7].

Resistance emergence is evolutionary and expected [8,9].

2.4. Semi-Quantitative Model: Genomic Effective Target Coverage (GETC)

Define: GETC ≈ Eligibility × Response Rate × Tumor-Cell Coverage × Durability Factor

Illustrative sensitivity framing (conceptual): Each term in GETC is constrained by real-world structural factors—population eligibility, partial tumor-clone coverage due to ITH, and time-limited durability due to resistance. When these constraints are compounded multiplicatively, the resulting effective coverage (i.e., the fraction of the total metastatic population experiencing meaningful, durable, multi-clonal control) can shrink substantially even when each individual factor appears clinically meaningful in isolation.

Illustrative scenario (conceptual): Using published estimates of eligibility (~14%[1,2]), response among eligible (often ~40–60% depending on tumor type [5,6,7]), partial clonal coverage [3,4], and time-limited durability (based on reported median PFS durations [5,6,7]), the resulting effective coverage would approximate 2–3% of the overall metastatic population under these assumptions.

These parameters vary substantially across tumor types, biomarkers, and lines of therapy; this calculation is intended to illustrate multiplicative constraint rather than provide a definitive epidemiologic estimate.

This formulation is not intended as a definitive measurement. Rather, it formalizes a systems principle: single-node genomic precision does not automatically translate into system-wide tumor control, because eligibility, clonal coverage, and durability are structurally limiting multipliers.

The practical implication is that high molecular precision does not necessarily translate into broad tumor-system impact.

3. A Dual-Axis Framework: Specificity vs Distribution

Targeted therapies should be evaluated along two axes:

• Axis A — Specificity of Target: Molecular precision.
• Axis B — Distribution of Vulnerability: Prevalence of the exploited vulnerability across tumor types and tumor cells.

Genomic targeting: High specificity / Low distribution.

Redox targeting: Moderate specificity / Moderate-to-broad distribution.

Metabolic targeting: Moderate specificity / Broad distribution.

4. Layer 2 — Redox Targeting and the Catalase Axis

4.1. Redox Fragility in Cancer

Cancer cells often operate under elevated reactive oxygen species (ROS) levels and exist near oxidative stress thresholds [16,17,18]. ROS-mediated targeting has been proposed as a radical therapeutic approach exploiting this non-oncogene vulnerability [15].

In a multi–cell line survey (15 tumor vs 10 normal cell lines), Doskey et al. quantified the rate constant for extracellular H₂O₂ removal (k_cell) and found that normal cells had ~2× higher H₂O₂ removal capacity than tumor cells on average, and that ascorbate sensitivity (ED₅₀) correlated with k_cell and catalase activity [17].

4.2. Catalase Distribution

Glorieux and Calderon reviewed catalase as a potential cancer treatment axis, noting frequent decreases in catalase across many tumors with context-specific exceptions [19].

Practically, this means catalase is not a binary marker (“low vs high”) but a distributed trait that varies across tumors and can be treated as a stratification axis rather than a yes/no inclusion criterion (formalized below as CVI)[19].

4.3. Mechanistic Coherence of Pharmacologic Ascorbate

At pharmacologic plasma concentrations achievable only via intravenous administration, ascorbate can generate extracellular H2O2 in the presence of redox-active metal ions. Tumor cells with limited catalase capacity may experience cytotoxic oxidative stress, whereas normal tissues with higher detox capacity may be relatively protected, creating a redox threshold differential.

Exposure (what dose can achieve): Pharmacologic ascorbate is typically defined in this literature as plasma ascorbate on the order of ≥~20 mM, achievable via IV delivery [17].

Contrast with oral: Oral vitamin C is tightly constrained; the NIH ODS fact sheet notes that oral dosing gives typical plasma peaks ~135 µmol/L after ~1.25 g oral vitamin C and IV administration can yield plasma concentrations ~26 mM (30,000 µmol/L) [20].

Pharmacologic ascorbate achieves millimolar plasma concentrations not attainable through oral dosing, generating extracellular hydrogen peroxide in the presence of catalytic iron and disrupting tumor iron metabolism [12]. Differential susceptibility between tumor and normal cells has been demonstrated in preclinical systems, particularly in KRAS- and BRAF-mutant contexts [10].

Emerging preclinical data suggest that pharmacologic ascorbate resistance may be mediated through enhanced peroxide detoxification in some tumors, highlighting the importance of multi-parametric vulnerability stratification [21]

While intravenous vitamin C is not an FDA-approved cancer therapy, the U.S. National Cancer Institute’s PDQ summary notes that IV vitamin C has been generally well tolerated in clinical trials, and the NIH Office of Dietary Supplements emphasizes that individuals receiving vitamin C for medical treatment should be under the care of a physician [22].

4.4. Catalase Vulnerability Index (CVI)

CVI defined across tiers:

• Tier 1 — Functional peroxide clearance;
• Tier 2 — Catalase protein expression;
• Tier 3 — CAT mRNA expression.

CVI operates on a continuum. Thus, Redox Targetable Fraction (RTF) is phenotype-distributed and potentially broader than mutation-defined subsets.

In this framework, “redox targeting” is not defined by a rare mutation but by a quantifiable vulnerability axis (peroxide clearance capacity), which in vitro shows a systematic tumor–normal differential (~2× on average) and correlates with pharmacologic-ascorbate sensitivity [17].

5. Layer 3—Metabolic/Systemic Targeting

5.1. Metabolic Heterogeneity Clarified

Cancer metabolism is plastic. Not all tumors are OxPhos-deficient [6]. However, a pan-cancer TCGA analysis (9,668 patients; 33 tumor types) stratified tumors into glycolysis/OXPHOS subtypes using a double-score framework [23], demonstrating that metabolic phenotypes are widely distributed across tumor types.

5.2. Insulin–IGF Axis as Systemic Vulnerability

Insulin and IGF signaling activate PI3K/AKT/mTOR pathways across multiple malignancies, promoting anabolic growth and survival [13,14]. Hyperinsulinemia has been associated with increased cancer progression risk [13]. Systemic reduction of insulin signaling through carbohydrate restriction or ketogenic metabolic therapy therefore represents host-mediated pathway modulation rather than mutation-specific targeting [15,24].

Ketogenic metabolic therapy lowers systemic insulin, alters glucose availability, and modulates host growth signaling—representing host-mediated targeting rather than mutation-layer targeting.

5.3. Metabolic Targetability Index (MTI)

MTI may integrate glycolysis/OXPHOS transcriptomic scores, insulin resistance metrics, and substrate dependency markers. MTI conceptualizes metabolic vulnerability on a distributed scale.

6. Comparative Targetable Fraction Summary

Plasticity and adaptation

Genomic targeting is precise but structurally narrow. Redox and metabolic targeting are less node-specific but broader in phenotypic distribution.

7. Counterarguments

• Redox and metabolic vulnerabilities are heterogeneous → Stratification (CVI/MTI) is necessary.
• Tumors adapt metabolically → Layered targeting may outperform single-layer approaches.
• Clinical trial evidence for HDIVC and ketogenic therapy is limited → This paper establishes conceptual legitimacy, not clinical equivalence.

8. Limitations

• CVI and MTI require prospective validation.
• GETC is conceptual rather than definitive.
• Redox and metabolic clinical trial data remain emerging.
• This framework is theoretical and integrative.

9. Global Vulnerability Architecture

Hierarchical targeting model: GENOMIC → REDOX → METABOLIC → HOST SYSTEM. Each higher layer affects broader biological domains.

Replication stress dependency [25,26,27], ferroptosis susceptibility [28,29], hypoxia adaptation [30,31], and proteotoxic stress buffering [32,33] represent pan-cancer liabilities that extend beyond mutation-defined subsets.

10. Conclusions

Genomic targeted therapies represent an important advance. However, they do not constitute a general theory of cancer targeting. Redox and metabolic targeting address distributed biological vulnerabilities that may span broader tumor fractions and operate at higher systemic levels. A comprehensive oncology doctrine should integrate all layers of vulnerability rather than equating targeting exclusively with mutation-specific pharmacology. This manuscript establishes a formal conceptual framework for such integration. In this framework, genomic, redox, and metabolic targeting are not competitors but interoperable layers; combining them is the logical systems strategy for improving coverage across heterogeneous tumor ecosystems. For patients and clinicians seeking systems-level strategies beyond mutation-matched pharmacology, redox and metabolic targeting represent rational, biologically grounded extensions of the targeting concept rather than departures from it.